Urdorf, Switzerland

Miroslav Kosar

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Miroslav Kosar: Innovator in Heterocyclic Compounds

Introduction

Miroslav Kosar is a notable inventor based in Urdorf, Switzerland. He has made significant contributions to the field of chemistry, particularly in the development of heterocyclic compounds. His innovative work has led to the creation of new compounds that have various applications in the industry.

Latest Patents

Miroslav Kosar holds 1 patent for his invention related to heterocyclic compounds. The patent provides new heterocyclic compounds characterized by the general formula (I), where R, R, X, and Y are defined within the patent documentation. This invention includes compositions that utilize these compounds, processes for manufacturing them, and methods for their application.

Career Highlights

Throughout his career, Miroslav Kosar has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Miroslav has had the opportunity to work alongside talented individuals such as Carsten Kroll and Maurice Biedermann. These collaborations have enriched his research and have played a crucial role in the advancement of his inventions.

Conclusion

Miroslav Kosar's contributions to the field of heterocyclic compounds demonstrate his innovative spirit and dedication to scientific advancement. His work continues to influence the industry and pave the way for future discoveries.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…